CorMedix (CRMD) is a buy with its financial turnaround, robust growth, and first-mover advantage in the US dialysis market.

Trump’s tariffs and the global trade war continue to affect markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq Composite.

Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant ...

Relative to drug developers, medical device makers have outperformed amid the turmoil of the Trump administration's healthcare reforms.

IO Biotech ( ($IOBT) ) has issued an update. IO Biotech, Inc. faced a compliance issue with Nasdaq’s minimum bid price requirement when its stock ...

Regencell's stock soared 17,000% fueled by speculation, despite no revenue or clinical progress. Read why I think the RGC ...

Merck submitted a nonbinding offer for the smaller biotech earlier in the year, according to a media report citing people ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

The ASX biotech sector dipped slightly in value in May, but stocks such as Medadvisor and Dimerix recorded lusty gains.

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...